Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies.
NGS
clinical validation
diagnostic testing
gene panel
genetic testing
hematologic malignancies
myeloid
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
03
2019
revised:
27
05
2019
accepted:
03
06
2019
pubmed:
10
6
2019
medline:
25
1
2020
entrez:
10
6
2019
Statut:
ppublish
Résumé
The diagnosis of hematologic malignancies integrates multiple diagnostic and clinical disciplines. Historically, targeted (single-analyte) genetic testing has been used as reflex to initial prescreening by other diagnostic modalities including flow cytometry, anatomic pathology, and clinical cytogenetics. Given the wide range of mutations associated with hematologic malignancies a DNA/RNA-based NGS panel can provide a more effective and economical approach to comprehensive testing of patients as an initial, tier-1 screen. Using a cohort of 380 patients, we performed clinical validation of a gene panel designed to assess 40 genes (DNA), and 29 fusion driver genes with over 600 gene fusion partners (RNA), including sample exchange data across three clinical laboratories, and correlation with cytogenetic testing results. The clinical validation of this technology demonstrated that its accuracy, sensitivity, and specificity are comparable to the majority of targeted single-gene approaches, while assessment of the initial patient cohort data demonstrated a high diagnostic yield of 50.5%. Implementation of a tier-1 NGS-based protocol for gene panel screening provides a comprehensive alternative to targeted molecular testing in patients with suspected hematologic malignancies, with increased diagnostic yield, scalability, reproducibility, and cost effectiveness, making it ideally suited for implementation in clinical laboratories.
Substances chimiques
Biomarkers, Tumor
0
Oncogene Proteins, Fusion
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178-189Subventions
Organisme : London Health Sciences Centre Pathology and Laboratory Medicine Research and Innovation Fund
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Alonso CM, Llop M, Sargas C, et al. Clinical utility Of a next-generation sequencing panel for acute myeloid leukemia diagnostics. J Mol Diagn. 2018;21(2):228-240.
Au CH, Wa A, Ho DN, Chan TL, Ma ES. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms. Diagn Pathol. 2016;11:11.
Conte N, Varela I, Grove C, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia. 2013;27(9):1820-1825.
de Noronha TR, Mitne-Neto M, Chauffaille ML. Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification. J Investig Med. 2017;65(8):1155-1158.
Eisfeld A-K, Kohlschmidt J, Mrózek K, et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018;32(6):1338-1348.
Han X, Li W, He NA, et al. mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis. Clin Chimica Acta. 2018;479:25-37.
Haslam K, Catherwood MA, Dobbin E, Sproul A, Langabeer SE, Mills KI. Inter-laboratory evaluation of a next-generation sequencing panel for acute myeloid leukemia. Mol Diagn Ther. 2016;20(5):457-461.
Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J. Genetic landscape of acute myeloid leukemia interrogated by next-generation sequencing: a large cancer center experience. Cancer Genomics Proteomics. 2018;15(2):121-126.
Lin P-H, Li H-Y, Fan S-C, et al. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice. Cancer Med. 2017;6(2):349-360.
Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3):465-473.
Marjanovic I, Kostic J, Stanic B, et al. Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease. Tumour biol. 2016;37(10):13391-13401.
Thakral G, Vierkoetter K, Namiki S, et al. AML multi-gene panel testing: a review and comparison of two gene panels. Pathol Res Pract. 2016;212(5):372-380.
Wang B, Liu Y, Hou G, et al. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. Oncotarget. 2016;7(22):32065-32078.
Yan B, Hu Y, Ng C, et al. Coverage analysis in a targeted amplicon-based next-generation sequencing panel for myeloid neoplasms. J Clin Pathol. 2016;69(9):801-804.
Bartels S, Schipper E, Hasemeier B, Kreipe H, Lehmann U. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. Oncotarget. 2016;7(21):30084-30093.
Galanina N, Bejar R, Choi M, et al. Comprehensive genomic profiling reveals diverse but actionable molecular portfolios across hematologic malignancies: implications for next generation. Clinical Trials. Cancers. 2018;11(1):11.
He J, Abdel-Wahab O, Nahas MK, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016;127(24):3004-3014.
Ivanova M, Shivarov V, Pavlov I, Lilakos K, Naumova E. Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies. Molecular diagnosis & therapy. 2016;20(1):27-32.
Maes B, Willemse J, Broekmans A, et al. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics. Int J Lab Hematol. 2017;39(6):604-612.
Mukherjee S, Sathanoori M, Ma Z, et al. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies. Cancer genetics. 2017;216-217:128-141.
Reinig E, Yang F, Traer E, et al. Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia. Am J Clin Pathol. 2016;145(4):497-506.
Thomas M, Sukhai MA, Zhang T, et al. Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies. Arch Pathol Lab Med. 2017;141(6):759-775.
Delic S, Rose D, Kern W, et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol. 2016;175(3):419-426.
Kluk MJ, Lindsley RC, Aster JC, et al. Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies. J Mol Diagn. 2016;18(4):507-515.
Lasho TL, Mudireddy M, Finke CM, et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood advances. 2018;2(4):370-380.
Rigolin GM, Saccenti E, Bassi C, et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol. 2016;9(1):88.
Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood advances. 2016;1(1):21-30.
Ok CY, Patel KP, Garcia-Manero G, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015;39(3):348-354.
Shokeen Y, Sharma NR, Vats A, et al. Identification of prognostic and susceptibility markers in chronic myeloid leukemia using next generation sequencing. Ethiop J Health Sci. 2018;28(2):135-146.
Kim B, Lee H, Shin S, Lee ST, Choi JR. Clinical evaluation of massively parallel rna sequencing for detecting recurrent gene fusions in hematologic malignancies. J Mol Diagn. 2019;21(1):163-170.
Shen W, Paxton CN, Szankasi P, et al. Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing. J Clin Pathol. 2018;71(4):372-378.
Roy S, Coldren C, Karunamurthy A, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the association for molecular pathology and the college of american pathologists. J Mol Diagn. 2018;20(1):4-27.
Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and college of american pathologists. J Mol Diagn. 2017;19(1):4-23.
Castellanos E, Gel B, Rosas I, et al. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Sci Rep. 2017;7:39348.
Behdad A, Weigelin HC, Elenitoba-Johnson KS, Betz BL. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms. J Mol Diagn. 2015;17(1):76-84.
Bowman RL, Levine RL. TET2 in normal and malignant hematopoiesis. Cold Spring Harb Perspect Med. 2017;7(8):a026518.
Langabeer SE, Andrikovics H, Asp J, et al. Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol. 2015;95(4):270-279.
Hamblin A, Wordsworth S, Fermont JM, et al. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: retrospective validation and prospective audit in the UK national health service. PLoS Med. 2017;14(2):e1002230.
Shen W, Szankasi P, Sederberg M, et al. Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. Br J Haematol. 2016;173(1):49-58.
Selim AG, Moore AS. Molecular minimal residual disease monitoring in acute myeloid leukemia: challenges and future directions. J Mol Diagn. 2018;20(4):389-397.
Sung PJ, Luger SM. Minimal residual disease in acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(1):1.
Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize implements and enhances circular visualization in R. Bioinformatics. 2014;30(19):2811-2812.